Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SKB BIO) confirmed the completion of a private placing of 5.84 million new H shares on 10 July 2026.

The shares were issued at HKD 470.20 each, implying gross proceeds of approximately HKD 2.75 billion. The new issuance represents 3.41% of SKB BIO’s previously issued share capital.

Following the placement: • Issued H shares (excluding treasury shares) rose from 170.98 million to 176.82 million. • No treasury shares were outstanding before or after the transaction. • No share repurchases or redemptions were reported.

The company stated that the placement was duly authorised by its board and executed in full compliance with Hong Kong Stock Exchange listing rules and all relevant regulatory requirements.